Genetic Duo: ATP13A2 and GBA1 Interactions Fuel Neurodegeneration Parkinson’s disease (PD) ranks as the second most prevalent neurodegenerative disorder following Alzheimer’s disease, impacting more than 10 million individuals globally. The condition manifests thr

Genetic Duo: #ATP13A2 and #GBA1 Interactions Fuel #Neurodegeneration. M. Gu and H Bellen explain their findings. @bcmhouston.bsky.social #TexasChildrens
@molneurodegen.bsky.social @bcmgenetics.bsky.social #BCMPostDoc bioengineer.org/genetic-duo-...

It takes two: Genes ATP13A2 and GBA1 interact to drive neurodegeneration Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease, affecting more than 10 million people worldwide. People with this condition may experience tremo...

How do two altered genes, #ATP13A2 and #GBA1, in two different cell types lead to neurodegeneration? M. Gu and H Bellen explain their findings. @bcmhouston.bsky.social #TexasChildrens @molneurodegen.bsky.social @bcmgenetics.bsky.social #BCMPostDoc medicalxpress.com/news/2026-02...

Two #lysosomal genes ATP13A2 and #GBA1 interact to drive #neurodegeneration

Mingxue Gu, Jinghan Zhao, Mingxi Deng...Joshua M. Shulman & Hugo J. Bellen @bcmhouston.bsky.social #Parkinsons

link.springer.com/article/10.1...

Multi-omics insights into GBA1-associated Parkinson’s disease: interplay of genomics, transcriptomics, proteomics, and lipidomics - Molecular Neurodegeneration Molecular Neurodegeneration - Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder worldwide. The pathogenesis of PD is driven by multifactorial mechanisms...

Multi-omics insights into #GBA1 -associated #Parkinsons disease: interplay of #genomics, #transcriptomics, #proteomics, and #lipidomics

Yang Ni, Huaibin Cai, Yaping Shao, Weidong Le

link.springer.com/article/10.1...

Ziv Gan-Or, executive director of the Clinical Research Unit at The Neuro and the GBA1-Can Initiative speaks eSleep Europe virtual congress 2025.

NeuroCRU exec dir @zivganor.bsky.social
gave a keynote talk at #SleepEurope virtual congress discussing his lab’s work on the genetics of REM Sleep Behavior Disorder #RBD, allowing researchers to find #genetic targets like #GBA1 for #drugdevelopment and to identify patients best suited to trials.

Neuro CRU's Ziv Gan-Or leads the GBA1-Canada initiative, an open science platform dedicated to advancing research and treatment for #Parkinsons due to mutations in the #GBA1 gene. GBA1-CAN international conference: June 5-7. Deadline for abstracts: March 31. Register: lnkd.in/eNbQBhvW

Ziv Gan-Or, executive director of the Clinical Research Unit at The Neuro, presents his lab's work on the GBA1 mutation, responsible for a rare form of Parkinson's Disease during the 6th international Congress on Rare Diseases in Vienna. #Rare2025

CRU exec director @ZivGanOr was in Vienna for #RARE2025 to discuss his lab’s work understanding #GBA1, a genetic mutation behind a rare subtype of #Parkinsons. The CRU works to offer the most advanced investigational therapies for individuals with rare diseases, including RNA and #genetherapy.

Ziv Gan-Or

Dr. Ziv Gan-Or, co-director of The Neuro's Clinical Research Unit, describes the G-CAN project, focusing on people with the #GBA1 mutation, linked to Lewy body #dementia and Parkinson’s. The research group wants to test a new treatment within five years, and one to two more within ten years.